These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

601 related articles for article (PubMed ID: 17551473)

  • 21. Familial medullary carcinoma prevention, risk evaluation, and RET in children of families with MEN2.
    Moore SW; Appfelstaedt J; Zaahl MG
    J Pediatr Surg; 2007 Feb; 42(2):326-32. PubMed ID: 17270543
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The genetic basis of hereditary medullary thyroid cancer: clinical implications for the surgeon, with a particular emphasis on the role of prophylactic thyroidectomy.
    Sakorafas GH; Friess H; Peros G
    Endocr Relat Cancer; 2008 Dec; 15(4):871-84. PubMed ID: 19015274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Usefulness of the genetic study in the diagnosis of medullary carcinoma of the thyroid].
    Rafecas A; Ribas Y; Villabona C; Viladrich M; Figueras J; Fabregat J; Torras J; Gómez JM; Jaurrieta E
    Med Clin (Barc); 1998 Nov; 111(16):619-22. PubMed ID: 9881336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple endocrine neoplasias type 2A and thyroid medullary carcinoma: an interdisciplinary challenge.
    Haecker FM; Oertli D; Gissler S; Zumsteg U; Avoledo P; von Schweinitz D
    Pediatr Surg Int; 2003 Apr; 19(1-2):62-4. PubMed ID: 12721726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Experience of prophylactic thyroidectomy in multiple endocrine neoplasia type 2A kindreds with RET codon 804 mutations.
    Learoyd DL; Gosnell J; Elston MS; Saurine TJ; Richardson AL; Delbridge LW; Aglen JV; Robinson BG
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):636-41. PubMed ID: 16343097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [C634R mutation of the protooncongene RET and molecular diagnosis in multiple endocrine neoplasia type 2 in a large Moroccan family].
    Benazzouz B; Hafidi A; Benkhira S; Chraibi A; Kadiri A; Hilal L
    Bull Cancer; 2008 Apr; 95(4):457-63. PubMed ID: 18495576
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Thyroid carcinomas and Hirschsprung's disease--10-year experience with molecular genetic testing of the RET proto-oncogene].
    Bendlová B; Dvoráková S; Václavíková E; Sýkorová V; Vlcek P; Skába R
    Vnitr Lek; 2006 Oct; 52(10):926-34. PubMed ID: 17063805
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thyroid cancer genetics: multiple endocrine neoplasia type 2, non-medullary familial thyroid cancer, and familial syndromes associated with thyroid cancer.
    Richards ML
    Surg Oncol Clin N Am; 2009 Jan; 18(1):39-52, viii. PubMed ID: 19056041
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Medullary thyroid carcinoma: state of the art.
    Favia G; Iacobone M
    G Chir; 2005; 26(11-12):405-9. PubMed ID: 16472416
    [TBL] [Abstract][Full Text] [Related]  

  • 31. RET proto-oncogene mutations are restricted to codons 634 and 918 in mainland Chinese families with MEN2A and MEN2B.
    Zhou Y; Zhao Y; Cui B; Gu L; Zhu S; Li J; Liu J; Yin M; Zhao T; Yin Z; Yu C; Chen C; Wang L; Xiao B; Hong J; Zhang Y; Tang Z; Wang S; Li X; Ning G
    Clin Endocrinol (Oxf); 2007 Oct; 67(4):570-6. PubMed ID: 17573899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple endocrine neoplasia type 2 and the RET protooncogene: from bedside to bench to bedside.
    Machens A; Dralle H
    Mol Cell Endocrinol; 2006 Mar; 247(1-2):34-40. PubMed ID: 16343738
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical and genetic profile of patients with medullary thyroid cancer treated in the Cancer Centre--Institute of Oncology in Warsaw].
    Czetwertyńska M; Kozłowicz-Gudzińska I; Stachlewska-Nasfeter E; Sromek M; Skasko E; Paszko Z
    Endokrynol Pol; 2006; 57(4):415-9. PubMed ID: 17006846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Application of genetic screening in families with hereditary medullary thyroid carcinoma.
    Frank-Raue K; Höppner W; Buhr H; Herfarth C; Ziegler R; Raue F
    Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():108-10. PubMed ID: 8981015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Diagnosis and treatment of syndrome of multiple endocrine neoplasia type 2].
    Kuznetsov NS; Bel'tsevich DG; Poliakova EIu; Vasil'ev EV; Nemtsova MV
    Khirurgiia (Mosk); 2002; (2):4-9. PubMed ID: 12418313
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Medullary carcinoma of the thyroid: diagnosis and therapy].
    Giuffrida D; Ferraù F; Bordonaro R; Mattina M; Priolo D; Aiello RA; Cordio S; Motta S; Failla G
    Clin Ter; 2000; 151(1):29-35. PubMed ID: 10822879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetic aspects of familial thyroid cancer.
    Morrison PJ; Atkinson AB
    Oncologist; 2009 Jun; 14(6):571-7. PubMed ID: 19465682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost analysis of DNA-based testing in a large Canadian family with multiple endocrine neoplasia type 2.
    Gilchrist DM; Morrish DW; Bridge PJ; Brown JL
    Clin Genet; 2004 Oct; 66(4):349-52. PubMed ID: 15355438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Multiple endocrine neoplasia syndromes. Type 2].
    Juodele L; Juozaityte E; Zindzius A; Pundzius J
    Medicina (Kaunas); 2005; 41(4):281-94. PubMed ID: 15864001
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current management of medullary thyroid cancer.
    Sippel RS; Kunnimalaiyaan M; Chen H
    Oncologist; 2008 May; 13(5):539-47. PubMed ID: 18515739
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.